Posted on Fri 16 Oct 2020, 11:14 AM

The antiviral drug remdesivir, considered one of the most promising COVID-19 treatments, turns out to do little to prevent deaths from the disease, according to a WHO-backed study.

Remdesivir, which was part of the experimental cocktail given to US President Donald Trump when he caught the new coronavirus last month, was one of several reviewed in a large study of more than 11,000 people across 30 countries.

The drug “appeared to have little or no effect on hospitalised COVID-19, as indicated by overall mortality, initiation of ventilation, and duration of hospital stay,” said the study posted online late Thursday.

The data, which has yet to be peer-reviewed or published in a scientific journal, seems to contradict at least two major US studies that have shown that remdesivir can reduce the duration of hospital stays for COVID-19 patients.

Washington authorised the emergency use of the medicine, made by US pharmaceutical company Gilead Sciences and originally intended as a treatment for Ebola — on May 1, followed by a range of other countries and the European Union.

-AFP

 

Add new comment

Filtered HTML

  • Web page addresses and e-mail addresses turn into links automatically.
  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
By submitting this form, you accept the Mollom privacy policy.
Get the Latest News updates from Homeland New. Read more
Phone: +234 818 217 4858
Email: info@homelandnewsng.com

Newsletter

Subscribe to our Newsletter to get latest updates!

Connect With Us